The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1631
ISSUE 1631
August 23, 2021
Issue 1631
- In Brief: Shingrix for Immunocompromised Adults
- Casirivimab and Imdevimab (REGEN-COV) for Post-Exposure Prophylaxis of COVID-19
- Finerenone (Kerendia) for Chronic Kidney Disease
- Dasiglucagon (Zegalogue) for Severe Hypoglycemia
- Voclosporin (Lupkynis) for Lupus Nephritis
- In Brief: Oritavancin (Kimyrsa) for Skin and Skin Structure Infections (online only)
- In Brief: A Shorter Treatment Regimen for Tuberculosis (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
In Brief: Shingrix for Immunocompromised Adults
August 23, 2021 (Issue: 1631)
The FDA has licensed the adjuvanted, recombinant
varicella zoster virus (VZV) vaccine Shingrix (GSK) for
prevention of herpes zoster (shingles) in adults of any
age who are or will be at elevated risk because of disease-
or therapy-induced...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.